Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
147
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

336
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
336
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

285
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
285
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

330
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
330

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity-dependent antioxidant gene therapy protects against epileptogenesis.

Signal transduction and targeted therapy·2026
Same author

Energy metabolism, adenosine, and glutamate signaling reprogramming by decanoic acid in Glut1 disorder syndrome.

Epilepsia open·2026
Same author

The heartbeat evoked potential and the prediction of functional seizure semiology.

Brain communications·2026
Same author

Metabolic targeting of pantothenate by medium chain fats in glioblastoma cells.

BMC cancer·2026
Same author

Dual mechanism of anti-seizure medications in controlling seizure activity.

Brain communications·2026
Same author

Does having bad epilepsy make you a good surgical candidate? A number needed to treat analysis.

Epilepsia open·2026

Related Experiment Video

Updated: Jun 9, 2025

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.5K

Drug repurposing in status epilepticus.

Matthew C Walker1

  • 1Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London WC1N 3BG, UK.

Epilepsy & Behavior : E&B
|October 28, 2024
PubMed
Summary
This summary is machine-generated.

Drug repurposing offers a cost-effective solution for developing new treatments for status epilepticus (SE). Novel computational and biological methods identify promising repurposed drugs, overcoming traditional development challenges.

Keywords:
Artificial intelligenceDrug repurposingGenomicsNeuroinflammationReactive oxygen speciesStatus epilepticus

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K
Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
06:28

Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems

Published on: September 27, 2024

2.2K

Related Experiment Videos

Last Updated: Jun 9, 2025

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.5K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K
Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
06:28

Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems

Published on: September 27, 2024

2.2K

Area of Science:

  • Neuroscience and Pharmacology
  • Computational Biology and Artificial Intelligence

Background:

  • Status epilepticus (SE) treatment has seen minimal advancement in two decades due to high drug development costs and risks.
  • SE presents unique challenges for drug development, including patient variability and the need for acute, not chronic, treatment strategies.
  • Limited industry interest in novel drug development for SE necessitates alternative approaches.

Purpose of the Study:

  • To explore drug repurposing as a viable strategy to address unmet needs in status epilepticus treatment.
  • To demonstrate the application of integrated biological and computational methods for identifying repurposed drugs for SE.
  • To highlight potential candidate drugs identified through these novel approaches.

Main Methods:

  • Biological approaches focused on mechanisms of drug resistance and long-term consequences in SE.
  • Computational methods, including artificial intelligence (AI) platforms and in silico analysis of gene expression, to predict molecular targets.
  • Integration of AI and in silico findings to generate and validate lists of potential repurposed drugs.

Main Results:

  • Identified several candidate drugs, including metformin, sirolimus, and riluzole, for SE treatment through combined AI and in silico approaches.
  • Biological strategies explored mechanisms of drug resistance and long-term SE effects, suggesting drugs like ketamine and omaveloxolone.
  • Drug repurposing demonstrated advantages in reduced development time, lower costs, and potentially higher success rates.

Conclusions:

  • Drug repurposing presents a promising and viable solution to accelerate the development of new treatments for status epilepticus.
  • Despite challenges like intellectual property and regulatory hurdles, repurposing can overcome the slow progress and high costs of traditional drug development.
  • The integration of biological insights with advanced computational methods offers a powerful framework for future SE drug discovery.